ClinicalTrials.Veeva

Find clinical trials for Acute Myeloid Leukemia (AML) in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Sevilla, AN, ESP:

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Sevilla, Spain and 164 other locations

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

The purpose of the phase 1 portion (dose escalation) of the study will be to establish an optimally safe and biologically active recommended phase 2...

Enrolling
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Acute Myeloid Leukemia (AML)
Drug: fludarabine
Drug: cytarabine

Phase 1, Phase 2

Astellas
Astellas

Sevilla, Spain and 24 other locations

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission (QUAZAR AML-001)

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Sevilla, Spain and 222 other locations

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase....

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Sevilla, Spain and 51 other locations

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-type Acute...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Cytarabine
Drug: Quizartinib

Phase 2

PETHEMA Foundation

Sevilla, Spain and 44 other locations

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ...

Enrolling
Acute Mixed-Phenotype Leukemia
Chronic Lymphocytic Leukemia
Drug: BMF-219

Phase 1

Biomea Fusion

Sevilla, Spain and 40 other locations

A Study of BGB-11417 in Participants With Myeloid Malignancies

monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodyspla...

Enrolling
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Drug: BGB-11417
Drug: Posaconazole

Phase 1, Phase 2

BeiGene
BeiGene

Sevilla, Spain and 40 other locations

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (REGAL)

available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second ...

Active, not recruiting
Acute Myeloid Leukemia
Biological: Galinpepimut-S
Drug: Azacitidine

Phase 3

Sellas Life Sciences

Sevilla, Spain and 72 other locations

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

efficacy and safety of the combination of oral quizartinib and FLAG-IDA chemotherapy schedule (FLAG-QUIDA regimen) in first relapsed/refractory AML...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Idarubicin
Drug: Quizartinib

Phase 1, Phase 2

PETHEMA Foundation

Sevilla, Spain and 19 other locations

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

myeloid leukemia (AML) in transfusion-dependent participants with low or immediate-1 risk MDS that is relapsed/refractory...

Active, not recruiting
Myelodysplastic Syndromes
Drug: Imetelstat
Drug: Placebo

Phase 2, Phase 3

Geron

Sevilla, Spain and 126 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems